The American Modern Society of Clinical Oncology–College of American Pathologists (ASCO–CAP) guidelines have continued to evolve to improve the precision and clinical utility of HER2 screening by providing particular algorithms15,16. In parallel with existing approaches, novel strategies to quantify HER2 stages or standardize strategies are now being investigated, which includes https://www.directivepublications.org/journal-of-clinical-breast-cancer/